Opinion|Videos|November 18, 2024
Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates
Author(s)Michael Levy, MD, PhD
Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have led to increased relapse rates.
Advertisement
Video content above is prompted by the following:
- Briefly review the current treatment landscape for aquaporin-4 IgG–seropositive (AQP4-IgG+) NMOSD and the role of anti-CD20 therapies, particularly rituximab.
- Could you speak to the clinical significance of these findings and their implications for the neurology community?
- How do these data compare to what you see in your clinical practice?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Friday 5 — September 12, 2025
5